Activity Overview
This online, on-demand virtual symposium brings together renowned experts in acute myeloid leukemia (AML). In this educational program, these experts review the pivotal, practice-changing data regarding the use of menin inhibitors in treating AML and lead case-based panel discussions to dissect the clinical implications and best practices for using these new agents in the clinic today.
This educational activity is an archive of the live symposium held on February 27, 2026.
Target Audience
This educational activity is directed toward hematologist-oncologists, advanced practice providers, and nurses involved in the treatment/management of patients with acute myeloid leukemia (AML).
Learning Objectives
Upon participation in this activity, learners will be better able to:
- Describe the mechanism of action of menin inhibitors as a therapeutic strategy for AML
- Evaluate the latest efficacy and safety data of menin inhibitors in the treatment of patients with KMT2A-rearranged and NPM1-mutated relapsed/refractory AML
- Individualize therapy for patients with KMT2A-rearranged and NPM1-mutated relapsed/refractory AML based on evidence-based guidelines
- Apply recommended strategies to mitigate and manage adverse events associated with menin inhibitors in patients with AML
GET STARTED WITH THIS PROGRAM:
Register now to gain access to this program.
Create AccountAlready Registered? Login Here